[8-K] Theravance Biopharma, Inc. Reports Material Event
Theravance Biopharma notified investors that it has issued a press release and will hold a conference call presenting its financial results for the quarter ended June 30, 2025 and a business update.
The materials supporting the call are being furnished as Exhibit 99.1 (press release) and Exhibit 99.2 (slide deck). The filing states these exhibits are furnished and not filed, which limits certain statutory liabilities associated with filed disclosures.
Theravance Biopharma ha informato gli investitori di aver diffuso un comunicato stampa e di tenere una conference call per illustrare i risultati finanziari del trimestre chiuso al 30 giugno 2025 e fornire un aggiornamento sull'attivit脿 aziendale.
I materiali a supporto della call sono forniti come Exhibit 99.1 (comunicato stampa) e Exhibit 99.2 (presentazione). La comunicazione precisa che tali exhibit sono forniti e non depositati, limitando cos矛 alcune responsabilit脿 legali previste dalla legge connesse alle comunicazioni depositate.
Theravance Biopharma notific贸 a los inversores que ha emitido un comunicado de prensa y celebrar谩 una conferencia telef贸nica para presentar sus resultados financieros del trimestre concluido el 30 de junio de 2025 y ofrecer una actualizaci贸n sobre el negocio.
Los materiales que respaldan la llamada se est谩n proporcionando como Exhibit 99.1 (comunicado) y Exhibit 99.2 (presentaci贸n de diapositivas). El documento indica que estos anexos se proporcionan y no se presentan, lo que limita ciertas responsabilidades legales asociadas con las divulgaciones presentadas.
Theravance Biopharma電� 韴瀽鞛愲摛鞐愱矊 氤措弰鞛愲毳� 氚绊彫頃橁碃 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 攵勱赴鞚� 鞛鞁れ爜瓿� 靷梾 順勴櫓鞚� 氚滍憸頃橂姅 旎嵓霟办姢 旖滌潉 臧滌禍頃� 瓴冹澊霛缄碃 韱奠頄堨姷雼堧嫟.
旖滌潉 霋冯皼旃晿電� 鞛愲電� 氤措弰鞛愲鞚� Exhibit 99.1鞕� 鞀澕鞚措摐 雿绊伂鞚� Exhibit 99.2搿� 鞝滉车(蹿耻谤苍颈蝉丑别诲)霅橁碃 鞛堨姷雼堧嫟. 鞝滌稖 靹滊鞐愲姅 鞚措摛 鞝勳嫓鞛愲臧� 鞝滉车霅橃棃鞚� 肟� 鞝滌稖霅橃 鞎婌晿雼り碃 氇呾嫓霅橃柎 鞛堨溂氅�, 鞚措姅 鞝滌稖霅� 瓿奠嫓鞕� 甏�霠悳 鞚茧秬 氩曥爜 毂呾瀯鞚� 鞝滍暅頃╇媹雼�.
Theravance Biopharma a inform茅 les investisseurs qu'elle a publi茅 un communiqu茅 de presse et tiendra une conf茅rence t茅l茅phonique pour pr茅senter ses r茅sultats financiers pour le trimestre clos le 30 juin 2025 ainsi qu'une mise 脿 jour sur ses activit茅s.
Les documents accompagnant l'appel sont fournis sous la forme de Exhibit 99.1 (communiqu茅 de presse) et Exhibit 99.2 (diaporama). Le d茅p么t pr茅cise que ces pi猫ces sont fournies et non d茅pos茅es, ce qui limite certaines responsabilit茅s l茅gales li茅es aux divulgations d茅pos茅es.
Theravance Biopharma hat Investoren dar眉ber informiert, dass das Unternehmen eine Pressemitteilung herausgegeben hat und eine Telefonkonferenz abhalten wird, in der die Finanzergebnisse f眉r das zum 30. Juni 2025 abgeschlossene Quartal sowie ein Gesch盲ftsupdate pr盲sentiert werden.
Die die Konferenz unterst眉tzenden Unterlagen werden als Exhibit 99.1 (Pressemitteilung) und Exhibit 99.2 (Foliensatz) bereitgestellt. Die Einreichung weist darauf hin, dass diese Exhibits bereitgestellt und nicht eingereicht wurden, was bestimmte gesetzliche Haftungsrisiken im Zusammenhang mit eingereichten Offenlegungen einschr盲nkt.
- None.
- None.
Insights
TL;DR: Routine earnings disclosure notice; no financial metrics included here, so immediate investor impact is limited.
The 8-K informs investors that the company has released a press release and accompanying slides and will host a conference call on results for the quarter ended June 30, 2025. Because this filing does not include financial statements or numeric performance data, it provides notice of an upcoming disclosure rather than new substantive financial information. Investors must review the furnished exhibits or listen to the call to assess earnings, guidance, or changes to the business outlook.
TL;DR: Disclosure appears procedurally standard; exhibits are clearly labelled as "furnished, not filed," which is customary to limit Section 18 liability.
The form follows common practice by furnishing the press release and slide deck as Exhibits 99.1 and 99.2 and stating that the materials are furnished rather than filed. This language signals standard legal treatment of the exhibits and does not expand the registrant's exposure to certain liability provisions. The filing indicates authorized distribution of these materials by senior management.
Theravance Biopharma ha informato gli investitori di aver diffuso un comunicato stampa e di tenere una conference call per illustrare i risultati finanziari del trimestre chiuso al 30 giugno 2025 e fornire un aggiornamento sull'attivit脿 aziendale.
I materiali a supporto della call sono forniti come Exhibit 99.1 (comunicato stampa) e Exhibit 99.2 (presentazione). La comunicazione precisa che tali exhibit sono forniti e non depositati, limitando cos矛 alcune responsabilit脿 legali previste dalla legge connesse alle comunicazioni depositate.
Theravance Biopharma notific贸 a los inversores que ha emitido un comunicado de prensa y celebrar谩 una conferencia telef贸nica para presentar sus resultados financieros del trimestre concluido el 30 de junio de 2025 y ofrecer una actualizaci贸n sobre el negocio.
Los materiales que respaldan la llamada se est谩n proporcionando como Exhibit 99.1 (comunicado) y Exhibit 99.2 (presentaci贸n de diapositivas). El documento indica que estos anexos se proporcionan y no se presentan, lo que limita ciertas responsabilidades legales asociadas con las divulgaciones presentadas.
Theravance Biopharma電� 韴瀽鞛愲摛鞐愱矊 氤措弰鞛愲毳� 氚绊彫頃橁碃 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 攵勱赴鞚� 鞛鞁れ爜瓿� 靷梾 順勴櫓鞚� 氚滍憸頃橂姅 旎嵓霟办姢 旖滌潉 臧滌禍頃� 瓴冹澊霛缄碃 韱奠頄堨姷雼堧嫟.
旖滌潉 霋冯皼旃晿電� 鞛愲電� 氤措弰鞛愲鞚� Exhibit 99.1鞕� 鞀澕鞚措摐 雿绊伂鞚� Exhibit 99.2搿� 鞝滉车(蹿耻谤苍颈蝉丑别诲)霅橁碃 鞛堨姷雼堧嫟. 鞝滌稖 靹滊鞐愲姅 鞚措摛 鞝勳嫓鞛愲臧� 鞝滉车霅橃棃鞚� 肟� 鞝滌稖霅橃 鞎婌晿雼り碃 氇呾嫓霅橃柎 鞛堨溂氅�, 鞚措姅 鞝滌稖霅� 瓿奠嫓鞕� 甏�霠悳 鞚茧秬 氩曥爜 毂呾瀯鞚� 鞝滍暅頃╇媹雼�.
Theravance Biopharma a inform茅 les investisseurs qu'elle a publi茅 un communiqu茅 de presse et tiendra une conf茅rence t茅l茅phonique pour pr茅senter ses r茅sultats financiers pour le trimestre clos le 30 juin 2025 ainsi qu'une mise 脿 jour sur ses activit茅s.
Les documents accompagnant l'appel sont fournis sous la forme de Exhibit 99.1 (communiqu茅 de presse) et Exhibit 99.2 (diaporama). Le d茅p么t pr茅cise que ces pi猫ces sont fournies et non d茅pos茅es, ce qui limite certaines responsabilit茅s l茅gales li茅es aux divulgations d茅pos茅es.
Theravance Biopharma hat Investoren dar眉ber informiert, dass das Unternehmen eine Pressemitteilung herausgegeben hat und eine Telefonkonferenz abhalten wird, in der die Finanzergebnisse f眉r das zum 30. Juni 2025 abgeschlossene Quartal sowie ein Gesch盲ftsupdate pr盲sentiert werden.
Die die Konferenz unterst眉tzenden Unterlagen werden als Exhibit 99.1 (Pressemitteilung) und Exhibit 99.2 (Foliensatz) bereitgestellt. Die Einreichung weist darauf hin, dass diese Exhibits bereitgestellt und nicht eingereicht wurden, was bestimmte gesetzliche Haftungsrisiken im Zusammenhang mit eingereichten Offenlegungen einschr盲nkt.
FAQ
What did Theravance Biopharma (TBPH) disclose in this Form 8-K?
Which exhibits were furnished with the 8-K?
Does the 8-K include financial metrics or results?
What does "furnished, not filed" mean in this 8-K?
How can investors obtain the detailed results referenced in this filing?
